Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Iqbal Hussain Sells 38,951 Shares

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Iqbal Hussain sold 38,951 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the sale, the insider directly owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Centessa Pharmaceuticals Trading Up 1.2%

Shares of CNTA stock opened at $25.48 on Wednesday. The business has a 50-day moving average price of $25.40 and a two-hundred day moving average price of $22.60. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $30.58. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The firm has a market cap of $3.43 billion, a P/E ratio of -13.92 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on CNTA. Stephens began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 target price on the stock. Oppenheimer upped their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Finally, Guggenheim raised their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $38.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. TD Waterhouse Canada Inc. bought a new position in Centessa Pharmaceuticals during the 4th quarter valued at approximately $25,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after buying an additional 979 shares during the period. Campbell & CO Investment Adviser LLC bought a new position in shares of Centessa Pharmaceuticals during the second quarter valued at approximately $218,000. DNB Asset Management AS purchased a new stake in Centessa Pharmaceuticals in the third quarter worth $218,000. Finally, Sigma Planning Corp bought a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $225,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.